• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat.Com. Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease

tetano

Editor, Senior Moderator
Nat Commun. 2018 Feb 26;9(1):824. doi: 10.1038/s41467-018-03243-7.
[h=1]Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease.[/h] Wang Z[SUP]1,[/SUP][SUP]2[/SUP], Zhu L[SUP]1[/SUP], Nguyen THO[SUP]2[/SUP], Wan Y[SUP]1[/SUP], Sant S[SUP]2[/SUP], Qui?ones-Parra SM[SUP]2[/SUP], Crawford JC[SUP]3[/SUP], Eltahla AA[SUP]4[/SUP], Rizzetto S[SUP]4[/SUP], Bull RA[SUP]4[/SUP], Qiu C[SUP]1[/SUP], Koutsakos M[SUP]2[/SUP], Clemens EB[SUP]2[/SUP], Loh L[SUP]2[/SUP], Chen T[SUP]1[/SUP], Liu L[SUP]1[/SUP], Cao P[SUP]5[/SUP], Ren Y[SUP]1[/SUP], Kedzierski L[SUP]2[/SUP], Kotsimbos T[SUP]6[/SUP], McCaw JM[SUP]5[/SUP], La Gruta NL[SUP]2,[/SUP][SUP]7[/SUP], Turner SJ[SUP]2,[/SUP][SUP]8[/SUP], Cheng AC[SUP]9[/SUP], Luciani F[SUP]4[/SUP], Zhang X[SUP]1[/SUP], Doherty PC[SUP]2,[/SUP][SUP]3[/SUP], Thomas PG[SUP]3[/SUP], Xu J[SUP]10[/SUP], Kedzierska K[SUP]11,[/SUP][SUP]12[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Severe influenza A virus (IAV) infection is associated with immune dysfunction. Here, we show circulating CD8[SUP]+[/SUP] T-cell profiles from patients hospitalized with avian H7N9, seasonal IAV, and influenza vaccinees. Patient survival reflects an early, transient prevalence of highly activated CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP]PD-1[SUP]+[/SUP] CD8[SUP]+[/SUP] T cells, whereas the prolonged persistence of this set is found in ultimately fatal cases. Single-cell T cell receptor (TCR)-αβ analyses of activated CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP]CD8[SUP]+[/SUP] T cells show similar TCRαβ diversity but differential clonal expansion kinetics in surviving and fatal H7N9 patients. Delayed clonal expansion associated with an early dichotomy at a transcriptome level (as detected by single-cell RNAseq) is found in CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP]CD8[SUP]+[/SUP] T cells from patients who succumbed to the disease, suggesting a divergent differentiation pathway of CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP]CD8[SUP]+[/SUP] T cells from the outset during fatal disease. Our study proposes that effective expansion of cross-reactive influenza-specific TCRαβ clonotypes with appropriate transcriptome signatures is needed for early protection against severe influenza disease.


PMID: 29483513 DOI: 10.1038/s41467-018-03243-7
 
Back
Top Bottom